Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration.
Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disorder. SMA is caused by homozygous loss of the SMN1 gene and retention of the SMN2 gene resulting in reduced levels of full length SMN protein that are insufficient for motor neuron function. Various treatments that restore leve...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5132001?pdf=render |
id |
doaj-70227867f0174afcaf850b9a879836ce |
---|---|
record_format |
Article |
spelling |
doaj-70227867f0174afcaf850b9a879836ce2020-11-25T00:07:26ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-011112e016707710.1371/journal.pone.0167077Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration.W David ArnoldSandra DuqueChitra C IyerPhillip ZaworskiVicki L McGovernShannon J TaylorKatharine M von HerrmannDione T KobayashiKaren S ChenStephen J KolbSergey V PaushkinArthur H M BurghesSpinal muscular atrophy (SMA) is an autosomal recessive motor neuron disorder. SMA is caused by homozygous loss of the SMN1 gene and retention of the SMN2 gene resulting in reduced levels of full length SMN protein that are insufficient for motor neuron function. Various treatments that restore levels of SMN are currently in clinical trials and biomarkers are needed to determine the response to treatment. Here, we sought to investigate in SMA mice a set of plasma analytes, previously identified in patients with SMA to correlate with motor function. The goal was to determine whether levels of plasma markers were altered in the SMNΔ7 mouse model of SMA and whether postnatal SMN restoration resulted in normalization of the biomarkers.SMNΔ7 and control mice were treated with antisense oligonucleotides (ASO) targeting ISS-N1 to increase SMN protein from SMN2 or scramble ASO (sham treatment) via intracerebroventricular injection on postnatal day 1 (P1). Brain, spinal cord, quadriceps muscle, and liver were analyzed for SMN protein levels at P12 and P90. Ten plasma biomarkers (a subset of biomarkers in the SMA-MAP panel available for analysis in mice) were analyzed in plasma obtained at P12, P30, and P90.Of the eight plasma biomarkers assessed, 5 were significantly changed in sham treated SMNΔ7 mice compared to control mice and were normalized in SMNΔ7 mice treated with ASO.This study defines a subset of the SMA-MAP plasma biomarker panel that is abnormal in the most commonly used mouse model of SMA. Furthermore, some of these markers are responsive to postnatal SMN restoration. These findings support continued clinical development of these potential prognostic and pharmacodynamic biomarkers.http://europepmc.org/articles/PMC5132001?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
W David Arnold Sandra Duque Chitra C Iyer Phillip Zaworski Vicki L McGovern Shannon J Taylor Katharine M von Herrmann Dione T Kobayashi Karen S Chen Stephen J Kolb Sergey V Paushkin Arthur H M Burghes |
spellingShingle |
W David Arnold Sandra Duque Chitra C Iyer Phillip Zaworski Vicki L McGovern Shannon J Taylor Katharine M von Herrmann Dione T Kobayashi Karen S Chen Stephen J Kolb Sergey V Paushkin Arthur H M Burghes Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration. PLoS ONE |
author_facet |
W David Arnold Sandra Duque Chitra C Iyer Phillip Zaworski Vicki L McGovern Shannon J Taylor Katharine M von Herrmann Dione T Kobayashi Karen S Chen Stephen J Kolb Sergey V Paushkin Arthur H M Burghes |
author_sort |
W David Arnold |
title |
Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration. |
title_short |
Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration. |
title_full |
Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration. |
title_fullStr |
Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration. |
title_full_unstemmed |
Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration. |
title_sort |
normalization of patient-identified plasma biomarkers in smnδ7 mice following postnatal smn restoration. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2016-01-01 |
description |
Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disorder. SMA is caused by homozygous loss of the SMN1 gene and retention of the SMN2 gene resulting in reduced levels of full length SMN protein that are insufficient for motor neuron function. Various treatments that restore levels of SMN are currently in clinical trials and biomarkers are needed to determine the response to treatment. Here, we sought to investigate in SMA mice a set of plasma analytes, previously identified in patients with SMA to correlate with motor function. The goal was to determine whether levels of plasma markers were altered in the SMNΔ7 mouse model of SMA and whether postnatal SMN restoration resulted in normalization of the biomarkers.SMNΔ7 and control mice were treated with antisense oligonucleotides (ASO) targeting ISS-N1 to increase SMN protein from SMN2 or scramble ASO (sham treatment) via intracerebroventricular injection on postnatal day 1 (P1). Brain, spinal cord, quadriceps muscle, and liver were analyzed for SMN protein levels at P12 and P90. Ten plasma biomarkers (a subset of biomarkers in the SMA-MAP panel available for analysis in mice) were analyzed in plasma obtained at P12, P30, and P90.Of the eight plasma biomarkers assessed, 5 were significantly changed in sham treated SMNΔ7 mice compared to control mice and were normalized in SMNΔ7 mice treated with ASO.This study defines a subset of the SMA-MAP plasma biomarker panel that is abnormal in the most commonly used mouse model of SMA. Furthermore, some of these markers are responsive to postnatal SMN restoration. These findings support continued clinical development of these potential prognostic and pharmacodynamic biomarkers. |
url |
http://europepmc.org/articles/PMC5132001?pdf=render |
work_keys_str_mv |
AT wdavidarnold normalizationofpatientidentifiedplasmabiomarkersinsmnd7micefollowingpostnatalsmnrestoration AT sandraduque normalizationofpatientidentifiedplasmabiomarkersinsmnd7micefollowingpostnatalsmnrestoration AT chitraciyer normalizationofpatientidentifiedplasmabiomarkersinsmnd7micefollowingpostnatalsmnrestoration AT phillipzaworski normalizationofpatientidentifiedplasmabiomarkersinsmnd7micefollowingpostnatalsmnrestoration AT vickilmcgovern normalizationofpatientidentifiedplasmabiomarkersinsmnd7micefollowingpostnatalsmnrestoration AT shannonjtaylor normalizationofpatientidentifiedplasmabiomarkersinsmnd7micefollowingpostnatalsmnrestoration AT katharinemvonherrmann normalizationofpatientidentifiedplasmabiomarkersinsmnd7micefollowingpostnatalsmnrestoration AT dionetkobayashi normalizationofpatientidentifiedplasmabiomarkersinsmnd7micefollowingpostnatalsmnrestoration AT karenschen normalizationofpatientidentifiedplasmabiomarkersinsmnd7micefollowingpostnatalsmnrestoration AT stephenjkolb normalizationofpatientidentifiedplasmabiomarkersinsmnd7micefollowingpostnatalsmnrestoration AT sergeyvpaushkin normalizationofpatientidentifiedplasmabiomarkersinsmnd7micefollowingpostnatalsmnrestoration AT arthurhmburghes normalizationofpatientidentifiedplasmabiomarkersinsmnd7micefollowingpostnatalsmnrestoration |
_version_ |
1725418247153516544 |